Prior infection with influenza virus but not vaccination leaves a long-term immunological imprint that intensifies the protective efficacy of antigenically drifted vaccine strains  by Kim, Jin Hyang et al.
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The role of pre-existing immunity for inﬂuenza vaccine responses is of great importance for public
health, and thus has been studied in various contexts, yet the impact of differential priming on vac-
cine responses in the midst of antigenic drift remains to be elucidated. To address this with antigenically
related viruses, mice were ﬁrst primed by either infection or immunization with A/Puerto Rico/8/34
(PR8) virus, then immunized with whole-inactivated A/Fort Monmouth/1/47 (FM1) virus. The ensu-
ing vaccine responses and the protective efﬁcacy of FM1 were superior in PR8 infection-primed mice
compared to PR8 immunization-primed or unprimed mice. Increased FM1-speciﬁc Ab responses of PR8nﬂuenza virus
nfection
ntigenic drift
accine efﬁcacy
andemic H1N1
infection-primed mice also broadened cross-reactivity against contemporary as well as antigenically
more drifted strains. Further, prior infection heightened the protective efﬁcacy of antigenically distant
strains, such as A/Brisbane/59/2006 infection followed by immunization with split pandemic H1N1 vac-
cine (A/California/07/2009). Therefore, inﬂuenza infection is a signiﬁcant priming event that intensiﬁes
future vaccine responses against drift strains.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://. Introduction
Recommendations by the US Advisory Committee on Immu-
ization Practices (ACIP) has helped improve overall inﬂuenza
accine coverage and reduce disease burden and mortality [1,2],
et inﬂuenza remains a signiﬁcant threat to public health [3].
nﬂuenza vaccine effectiveness (VE), currently estimated at 50–60%
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by theWorldHealth Organization (WHO), is inﬂuenced bymultiple
confounding factors including vaccine recipients’ age and health
status, virulence of the circulating strain as well as the VE study
design itself [4]. The antigenic relatedness between vaccine and
circulating strain also impacts the VE, such that emergence of anti-
genically drifted strains have caused vaccinemismatches, resulting
in increased infections and reduced VE [5–7]. The intermittent
infections by drifted strains may seem discouraging for the vacci-
nation effort, but it remains unclear how and to what extent these
infections can inﬂuence subsequent vaccine responses. A better
understanding of this issue can provide an important rationale for
continual seasonal inﬂuenza vaccinations.
While the role of a primary infection on heterosubtypic immu-
nity has been established in animal studies [8–12], its role on
subsequent vaccine responses is not well-known. Human studies
on this subject have been challenging, as it requires multi-year
longitudinal studies in a deﬁned cohort. However, recent stud-
ies provide valuable insights on what extent a single infection
can induce hemagglutination inhibition (HI) titers against his-
toric as well as contemporary strains in unvaccinated individuals,
termed ‘back-boost’ [13]. Back-boost was also detectable following
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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accination, but as often is the case in clinical studies, the indi-
iduals’ infection history and proper controls were not readily
easible, making it difﬁcult to delineate infection history as a com-
ounding factor for their Ab responses. In this study, we found
hat prior infection, but not immunization with PR8, intensiﬁed
mmunogenicity and efﬁcacy of killed FM1 vaccine and broad-
nedAbcross-reactivityagainst antigenically furtherdrifted strains
n mice. Interestingly, prior infection enhanced vaccine efﬁcacy
f even antigenically distant strains. The impact of prior infec-
ion was also long-lasting, as immunization as late as 1 year post
R8-infection enhanced FM1-speciﬁc Ab responses. Since primary
nfections hardly occur in naïve hosts, we also addressed whether
rimary infection could be modulated in immune host using vac-
ine mismatch scenarios. Collectively, our ﬁndings suggest that an
nﬂuenza infection strengthens the subsequent vaccine responses
gainst variants in quantity and quality, while the impact of infec-
ion can be attenuated by the host’s pre-existing immunity.
. Methods
.1. Cells, viruses and vaccines
Madin-Darby canine kidney (MDCK) cells were maintained in
ulbecco’s modiﬁed Eagle’s medium containing antibiotics, glu-
amine and 10% fetal bovine serum (FBS). Inﬂuenza viruses were
ropagated in 11-day-old embryonic chicken eggs and clariﬁed
llantoic ﬂuid was used for virus infection of mice. For prepara-
ion of whole-inactivated viruses (WIV), clariﬁed allantoic ﬂuid
as puriﬁed on discontinuous sucrose-gradient composed of 15%,
0% and 60% sucrose and inactivated with 4% w/v (=10%, v/v)
ormalin until no infectivitywas detected inMDCK cells. After titra-
ion of the HA unit (HAU) by hemagglutination (HA) assay, WIVs
700–1400 HAU/100l/mouse) were used as immunogens as pre-
iously described [14]. For the experiments assessing the impact
f prior infection on the immunization with antigenically distant
train, commercially available pandemic H1N1 (pH1N1) monova-
ent split vaccine (A/California/07/2009; Cal07, 15g HA/500l)
as used to immunize mice.
.2. Mice, immunizations, infection and tissue collection,
ronchoalveolar lavage (BAL), nasal wash
Balb/c mice, infection and immunization were previously
escribed [14]. Spleen, lung and lymph nodes were collected after
uthanizing mice with a lethal dose of Avertin (Sigma-Aldrich).
AL was collected by injecting 1mL PBS+0.5% bovine serum albu-
in (BSA) through the trachea with an 18G catheter. Nasal washes
ere collected by passing 0.5mL PBS+0.5% BSA through the nasal
assage. All animal studies were performed with the approval and
uidance of the Institutional Animal Care andUse Committees in an
ssociation for Assessment andAccreditation of Laboratory Animal
are International-accredited animal facility of Emory University
nd the CDC.
.3. Ab responses
Serum microneutralization (MN) and HI titers were previously
escribed [14]. Mucosal IgG and IgA responses of BAL and nasal
ashes were analyzed by ELISA. Nunc 96 well plates (Maxi-sorb)
ere coated with 100HAU whole inactivated virus (WIV), then
locked with 4% BSA in PBS-Tween for 1h. Ten-fold dilutions of
amples are added to the plates for 2h. Plates were then devel-
pedbybiotin--mouse IgG/IgA followedby streptavidin (SA)-HRP
Southern Biotech). The signals were developed using 1×TMB
ebioscience) andmeasured at 450nmusing aplate reader (Biotek).4 (2016) 495–502
2.4. Ab-secreting cells (ASCs) by ELISpot assay
ELISpot plates (Millipore) were coated with 100 HAU WIV
overnight and blocked with cRPMI-1640 media. Dilutions of cells
were added to plates and incubated overnight at 37 ◦C. Plate-bound
Abs were probed by biotin--mouse IgG, SA-alkaline phosphatase
(Southern Biotech), then Vector Blue Substrate Kit (Vector Lab).
Spots were counted using an ImmunoSpot® ELISPOT reader (Cel-
lular Technology Ltd.).
2.5. Lung lysates and plaque assay
Lung lysates were prepared by homogenizing lung tissues
through a 40m cell strainer with syringe plungers. Homogenates
were spun at 450× g for 20min at 4 ◦C and the supernatants were
assessed for virus titers via plaque assay as previously described
[14].
2.6. Monoclonal Ab staining and ﬂow cytometry
Cellswere stainedwithCD11b,CD95,CXCR5,CD3,CD8a (BDBio-
science); CD103, I-Ad, GL7, CD138, CD69, CD86, CD19 (Biolegend);
CD49b, F4/80, CD11b, CD11c, CD45, PD-1 (eBioscience). Virus-
speciﬁc CD8+ T cells were identiﬁed using H-2Kd/IYSTVASSL (HA)
and H-2Kd/TYQRTRALV (NP) pentamers (Proimmune). For in vitro
stimulation, cells were infected with PR8 or FM1 virus at a multi-
plicity of infection (MOI) of 1 for 1h. After incubation overnight and
addition of Golgi-Plug (BD) for the last 6h, cells were stained with
CD4 and CD8, permeabilized and stained with IFN, IL-2, TNF.
Cells were analyzed with a FORTESSA ﬂow cytometer (BD) and
FlowJo software (Tree Star, Inc.).
2.7. Statistics
Student’s t test was used to compare the Ab titers between
PR8 vs. FM1-speciﬁc responses following log2 transformation. For
multiple groups, one way analysis of variances with Bonferroni
post-test was used. For statistical designations, * denotes p<0.05;
** denotes p<0.02; *** denotes p<0.001.
3. Results
3.1. Prior infection, but not immunization with PR8 enhanced the
local and systemic Ab responses and virus-speciﬁc T cell response
following FM1-WIV immunization
To compare the vaccine responses in differential priming con-
texts, mice were either infected or immunized with PR8. Infection
dose (0.01× LD50) was chosen to achieve subclinical infection
(≤5% body weight (BW) loss; data not shown). At memory phase
(>d28), mice were immunized with FM1-WIV and the acute local
Ab responses in inguinal lymph nodes were assessed on d5
post-immunization. The %plasma cells were signiﬁcantly higher
in PR8inf/FM1imm than in PBS/FM1imm or PR8imm/FM1imm mice
(Fig. 1A). The differential local Ab response was also reﬂected
systemically in spleen by signiﬁcant Ag-speciﬁc ASC responses
(Fig. 1B). While FM1-WIV in naïve mice (PBS/FM1imm) induced
minimal ASC responses, it intensiﬁed PR8- and FM1-speciﬁc ASC
responses in PR8inf/FM1imm, but not in PR8imm/FM1imm mice. The
virus-speciﬁc (NP+) CD8 T cell response in local lymph nodes was
also signiﬁcantly higher in PR8inf/FM1imm compared to control
groups (Fig. 1C). However, virus-speciﬁc CD4 and CD8 T cells in
spleen were readily recalled upon in vitro stimulation as long
as the mice were previously infected with PR8 (Fig. 1D, Sup-
plemental Fig. 1A and B). Both PR8 and FM1 stimulated T cells
at comparable levels, indicating signiﬁcant cross-reactivity of T
J.H. Kim et al. / Vaccine 34 (2016) 495–502 497
Fig. 1. Prior infection, but not immunization with PR8 enhanced the local and systemic Ab responses and virus-speciﬁc T cell responses following FM1-WIV immunization.
Balb/c mice (5 mice/group) were infected i.n. with 0.01× LD50 mouse-adapted PR8 or immunized i.m. with 1400 HAU PR8-WIV or mock-infected. A month later, all mice
except controls (PR8inf/PBS) were immunized i.m. with 1400 HAU FM1-WIV. (A) Inguinal lymph nodes were collected at d5 post immunization and the frequency of plasma
c ted at
I tamer
e ere a
c
i
F
(ells (B220−CD138+) was analyzed by ﬂow cytometry. (B) Spleens were also collec
nﬂuenza virus NP-speciﬁc CD8 T cells in lymph nodes were stained with NP+ pen
gg-grown PR8 or FM1 at MOI 1 overnight then IFN-secreting CD4 or CD8 T cells well epitopes between the two viruses. On the other hand, prior
mmunization with PR8 failed to recall T cell responses upon
M1 immunization (PR8imm/FM1imm). Local follicular helper T cells
TFH) were also marginally induced in PR8inf/FM1imm comparedthe same time and PR8 vs. FM1-speciﬁc ASCs were analyzed by ELISPOT assay. (C)
s and analyzed by ﬂow cytometry. (D) Splenocytes were stimulated in vitro with
nalyzed by intracellular cytokine staining and ﬂow cytometry.to controls (Supplemental Fig. 1C). These data demonstrate that
prior infection, but not immunization elicits superior Ab responses
upon immunization with a drift strain. Concomitantly, virus-
speciﬁc CD8 T cells, normally poorly induced by killed vaccine,
498 J.H. Kim et al. / Vaccine 34 (2016) 495–502
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Fig. 2. Prior infection with PR8 heightened and broadened the Ab responses upon FM1 immunization and enhanced protective efﬁcacy of vaccine Ag. Balb/c mice (5
mice/group) were infected i.n. with 0.1× LD50 PR8 virus and then a month later immunized with 1400HAU FM1-WIV. (A and B) Mice were bled on d28 post PR8 infection
(d28-1◦) and days 7, 14 and 28 post FM1 immunization (d7-2◦ , d14-2◦ , d28-2◦) and tested for HI (A) and MN titers (B) against MDCK-cell grown PR8 and FM1 viruses. (C) The
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iruses as well as swine virus (Swine/30, New Jersey/76, USSR/77, New Caledonia/9
ith a lethal dose (100× LD50) of FM1 virus at d28 post immunization. Lung lysates
re recruited to the local immunization site at signiﬁcantly higher
evels.
.2. Prior infection with PR8 heightened and broadened the Ab
esponse upon FM1 immunization and enhanced protective
fﬁcacy of vaccine Ag
The enhanced acute responses in PR8inf/FM1imm mice (Fig. 1)
ed to development of robust FM1-neutralizing Abs (Fig. 2A and
). Upon FM1 immunization, a mixture of secondary and primary
b responses was detected in PR8inf/FM1imm mice; PR8-HI and
N titers were immediately boosted, while FM1-titers followed
rimary response kinetics. However, their FM1-titers were signif-
cantly higher than those of the PBS/FM1imm mice (Fig. 2A and B)
hich presented a genuine primary FM1-Ab response, and the rest
f the control groups (data not shown). The quantitative increase
n Ab titers was accompanied with expansion of cross-reactivity
Fig. 2C). Sera collected before and after FM1-WIV were tested
gainst A/Swine/Iowa/15/30, a historic swine H1N1 strain dur-
ng the 1930–1940s [15], as well as more antigenically drifted
trains that had circulated in later years in swine and/or humans
A/NewJersey/8/1976,A/USSR/90/1977,A/NewCaledonia/20/1999
nd A/Solomon Island/03/2006). The genetic relationship and dis-
ances of these viruses were recently reported [16]. While PR8
nfection elicited USSR/77- and Solomon Island/06-HI titers (d28-
◦), FM1 immunization induced additional cross-reactivity against
wine/30, New Jersey/76, and New Caledonia/99, and further
ncreased USSR/77- and Solomon Island/06-HI titers (d28-2◦).
n contrast, PBS/FM1imm mice developed cross-reactivity against
nly USSR/77 and Solomon Island/06. The protective efﬁcacy offor HI titers against other historic and antigenically drifted seasonal human H1N1
Solomon Island/06). (D) All immune mice and naïve control mice were challenged
collected on d4 following challenge and tested for virus titers via plaque assay.
FM1-WIV was, not surprisingly, superior in PR8inf/FM1imm than
in PBS/FM1imm mice, in a subsequent lethal challenge (Fig. 2D).
Lung virus titers at d4 post-challenge were undetectable in
PR8inf/FM1imm mice whereas 9.5×102 PFU/ml and 5×107 PFU/ml
were present in PBS/FM1imm and naïve mice, respectively. Thus,
while FM1-WIV reduced a lethal FM1 infection, prior PR8-infection
intensiﬁed the protective efﬁcacy of FM1-WIV. Since an infection
leaves life-long immune memory, the long-term impact of infec-
tion was tested by immunizing PR8-infected mice with FM1-WIV
either 3months or 1 year later (the length of this study). Regardless
of the length of time, prior PR8-infection elicited signiﬁcant FM1-
Ab titers upon FM1-WIV immunization (Supplemental Fig. 2A), and
all PR8inf/FM1imm mice survived lethal challenge (data not shown).
Furthermore, any change in the infection dose (0.01–0.1× LD50)
or immunization dose (700–1400 HAU) did not affect protective
efﬁcacy (Supplemental Fig. 2B and C).
3.3. Prior infection with Bris59 enhanced Ab responses and
protective efﬁcacy to the antigenically distant strain, Cal07, upon
immunization
Since antigenic distance is a major determinant for vaccine
efﬁcacy [17], the impact of prior infection on vaccine responses
may be conﬁned to antigenically related strains such as PR8/FM1
[14]. We tested whether this effect could be extended to antigeni-
cally and serologically distant viruses such as Bris59 and Cal07
(pH1N1) [16,18]. Infection with Bris59 followed by immuniza-
tion with pH1N1 vaccine immediately intensiﬁed Cal07-HI titers,
whereas titers of PBS/Cal07imm mice were fully developed at d28
post vaccination (Fig. 3A). Consistent with the serological distance
J.H. Kim et al. / Vaccine 34 (2016) 495–502 499
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Fig. 3. Prior infection with Bris59 enhanced the Ab response and protective efﬁcacy to the antigenically distant pandemic H1N1 strain, Cal07 upon immunization. Balb/c mice
(4–5 mice/group) were infected i.n. with Bris59 at 5×104 PFU or mock-infected with PBS or immunized i.m. with 09–10 seasonal trivalent inactivated vaccine containing
3g Bris59. A month later, all mice except control Bris59inf/PBS were immunized i.m. with monovalent pH1N1 (A/California/07/09) vaccine containing 3g HA. (A) Sera
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ll mice including naïve mice were challenged with A/Mexico/4108/09 at 8×106
hallenge and lung virus titers were analyzed via plaque assay.
etween Bris59 and Cal07, Bris59-HI titers were not boosted by
H1N1 immunization.When protective efﬁcacy of pH1N1 vaccines
as tested in subsequent lethal challenge with A/Mexico/4108/09
pH1N1), Bris59inf/Cal07imm mice showedmodestBWloss (Fig. 3B),
et had the lowest lung virus titers compared to various control
roups (Fig. 3C). These data emphasize the beneﬁt of subclinical
nfection in aiding subsequent vaccine responses even when the
accine strain is antigenically distant from the infecting strain.
.4. Attenuation of infection by prior immunization moderated
evelopment of protective immunity in an infection-dose
ependent manner
Several serosurveillance studies show that the general popu-
ation is immune to inﬂuenza virus likely due to prior infection
r immunization [19–23]. Therefore, while prior infection intensi-
es subsequent vaccine responses (Figs. 1–3), seasonal infections
ardly occur in naïve hosts, but rather as a result of vaccine mis-
atch. We, therefore, assessed whether and to what extent an
nfection can be modulated following mismatched vaccination, by
mmunizing mice ﬁrst with PR8-WIV, then infecting with 0.01
r 0.1× LD50 FM1. Following PR8-WIV-immunization, sera PR8-HI
nd MN titers were readily detected, yet FM1 cross-reactivity was
etected only by MN assay (Fig. 4A). However, mucosal (BAL and
asal washes) cross-reactive IgGs were comparable against both
iruses (Fig. 4A) with little IgA induction at either site (data not
hown). Upon FM1 infection, all mice showed minimal weight loss,
xcept PBS/FMinf (0.1) mice, which lost 5–6% BW (Supplemental
ig. 3A and B). However, lung virus titers of PR8imm/FM1inf mice
t d5 post-infection were signiﬁcantly lower than PBS/FM1inf mice
t each dose (Fig. 4B). Approximately 44% of PR8imm/FM1inf (0.01)
s well as 80% of PR8imm/PR8inf (0.1) mice (positive control) efﬁ-
iently cleared infection. The lung immune parameters reﬂected
he differential level of ongoing infections. Although%lung residentted against egg-grown Bris59 and Cal07 viruses. (B) A month after immunization,
d their BWs were monitored. (C) Lung lysates were collected on day 4 following
APC subsets (CD103+ vs. CD11b+) [24] was comparable among
groups (Supplemental Fig. 4A), their activation (CD86) was signif-
icantly lower in PR8imm/FM1inf compared to PBS/FM1inf mice at
each dose (Fig. 4C, Supplemental Fig. 4B). Likewise, lung inducible
TFH cells [25] were induced at comparable levels, yet their activa-
tion (CD69)was reduced in PR8imm/FM1inf compared to PBS/FM1inf
mice (Fig. 4C, Supplemental Fig. 4C). Germinal center (GC)-B cells
were not immediately affected by differentially activated TFH cells,
yet a differential level of activated B cells started to appear (Supple-
mental Fig. 4D).While themajorityof immuneparameters followed
this fashion, CD16/32 (FcR II/III) expression (Fig. 4D, Supplemental
Fig. 4E) on CD11b+ cells was signiﬁcantly higher in PR8imm/FM1inf
compared to PBS/FM1inf mice. Coincidently, signiﬁcantly more NP+
CD8 T cells were found in PR8imm/FM1inf than in PBS/FM1inf mice
(Fig. 5D). Since CD16/32 binds to immune complexes (ICs), this
implies that IC-mediated cross-presentation [26,27] is enhanced
in PR8imm/FM1inf mice. Virus-speciﬁc CD8 T cells recruited in this
manner may contribute to further viral clearance. The mice with
undetectable virus titers in Fig. 4B induced little to no activation
of APCs, NP+ CD8 T cells, GC-B cells or TFH cells (Supplemental Fig.
5A–D). Altogether, these data demonstrate that the degree of infec-
tion is mitigated even by mismatched vaccinations, yet in turn, the
development of humoral immunity against the infecting strain is
attenuated in an infection dose-dependent manner.
3.5. The infection dose-dependent acute responses led to the
differential proﬁle of FM1-speciﬁc protective immunity
Since attenuation of local immunity was evident, the develop-
ment of FM1-Ab responses was monitored at days 7, 14 and 28
post-infection. In PR8imm/FM1inf (0.01)mice, FM1-HI andMN titers
were signiﬁcantly less than those of PBS/FM1inf (0.01) mice, while
PR8-titers were boosted (Fig. 5A, Supplemental Fig. 6A). In con-
trast, FM1-titers of PR8imm/FM1inf (0.1) mice were comparable to
500 J.H. Kim et al. / Vaccine 34 (2016) 495–502
Fig. 4. Attenuation of infection by prior immunization moderated the development of protective immunity in an infection-dose dependent manner. Balb/c mice (9–10
mice/group) were immunized i.m. with 1400 HAU PR8-WIV or mock-immunized. (A) Sera, BAL and nasal wash samples were collected for assessment of Ab responses at d28
post immunization. Sera HI and MN titers were tested against PR8 and FM1 viruses (left panel). BAL and nasal washes were tested for virus-speciﬁc IgG by ELISA (right panel).
(B–D)Allmicewere infected i.n.with 0.01 or 0.1× LD50 mouse-adapted FM1virus.Mock infectedmice (PR8imm/PBS) andPR8imm/PR8inf (0.1)were set up as additional controls.
(B) Lung lysates were collected at d5 post infection and lung virus titers were analyzed by plaque assay. The numbers indicate mice with undetectable virus titers. (C and
D) Lung single cell suspensions were stained for APC subsets (CD11c+CD11b+, CD11c+CD103+), TFH cells (CD4+CXCR5+PD1+) and NP-speciﬁc CD8 T cells. (C) A representative
histogram of CD86 expression and its mean ﬂuorescence intensity (MFI) on CD11b+ subsets of all groups, a representative ﬂow chart of lung TFH (CD4+CXCR5+PD1+) cells and
their activation (CD69 MFI) of all groups are summarized. (D) A representative histogram of CD16/32 expression and its MFI on CD11b+ subsets of all groups, a representative
ﬂow chart of lung CD8+ T cells stained by NP or HA-pentamers and their summary of all groups are shown.
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Fig. 5. The infection dose-dependent acute responses led to a differential proﬁle of FM1-speciﬁc protective immunity. Balb/c mice (6–10 mice/group) were ﬁrst immunized
with 1400 HAU PR8-WIV and then infected with 0.01 or 0.1× LD50 FM1 virus at d28 post immunization. (A and B) Serum samples were collected at d28 post immunization
(d28-1◦), and days 7, 14 and 28 post FM1 infection (d7-2◦ , d14-2◦ , d28-d◦) for assessment of Ab responses. HI titers were tested against PR8 and FM1 viruses and shown
separately depending on infection dose for clarity. (C and D) A month after FM1 infection, mice were lethally challenged with 100× LD50 FM1 virus and lung lysates were
collected at d4 post challenge. Lung viral titers were assessed via plaque assay and plotted separately for clarity. The numbers indicate the mice with no detectable titers.
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hose of PBS/FM1inf (0.1) mice at 2 weeks and onward (Fig. 5B,
upplemental Fig. 6B). This dichotomy of the FM1-Ab responses
as sharply contrasted in protective immunity against FM1. Upon
ethal challenge, lung viral titers of PR8imm/FM1inf (0.01) mice
ere signiﬁcantly higher (6×105 PFU/ml) than PBS/FM1inf (0.01)
ice (Fig. 5C). In contrast, lung titers of PR8imm/FM1inf (0.1) mice
ere undetectable as in PBS/FM1inf (0.1) mice (Fig. 5D). Therefore,
nfection can be immediately attenuated even by mismatched vac-
ination, yet protective immunity against the infecting strain is
onsequently compromised in an infection dose-dependent man-
er.
. Discussion
Our ﬁndings demonstrate that infection leaves a long-lasting
mmunological imprint that boosts subsequent vaccine responses
gainst variants. Priming by infection, but not immunization con-
erred superior cell-mediated immune responses that were readily
ecruited to the local immunization site and were associated with
he augmented vaccine response. Clinical signiﬁcance of cellular
mmunity has been recently demonstrated in a human challenge
tudy and during the 2009 pH1N1 infection wave, by direct corre-
ation of pre-existing CD4or CD8T cell responses against conserved
cell epitopes with reduced virus shedding, disease symptoms
nd severity in neutralizing Ab-naïve individuals [28,29]. There-
ore, broadly cross-reactive cellular immunity conferred by prior
nfection may be directly responsible for the enhanced efﬁcacy of
ntigenically related as well as distant vaccine strains (Figs. 2–3).
On the other hand, inefﬁcient development of cellular immunity
y prior vaccination was associated with the immunogenicity and
rotective efﬁcacy of killed virus that was comparable to that of
aïve hosts (Figs. 2–3). Consistent to our ﬁndings, recent reports
howed that virus-speciﬁc CD8 T cell immunity was absent in
hildren who were annually vaccinated with inactivated inﬂuenza
accines (IIV), but observed in unvaccinated healthy children, who
ad presumably experienced infections during childhood [30]. Fur-
her, a recent study in children found that repeated prior IIV
accination during the previous 5 years was associated with lower
E in the current season compared to individuals with no prior
accination history [31]. It remains unknown whether an infection
pisode of the latter might have further impacted the current VE.
onsidering that live-attenuated inﬂuenza vaccine (LAIV) formula-
ion is available for healthy children age ≥2 and that LAIV has been
hown to induce signiﬁcantly better T cell immunity than IIV in
hildren [32–34], it will be of great clinical signiﬁcance to longitu-
inally investigate vaccine responses against antigenically drifted
trains in the LAIV-administered population.
Recent ﬁndings from limited vaccine trials showed that back-
oostwasachievedby immunization,with thehighest effectwithin
ntigenic clusters [13]. Since the degree of back boost was quite
ariable among individuals, it would be interesting to examine the
orrelation of individuals’ infection history and the degree of back
oost. Our ﬁndings highlight the impact of infection in expand-
ng the breadth of Ab responses to antigenically far-evolved strains
rom the infecting strain, as well as increasing the magnitude of
b responses to the vaccine strain itself (Fig. 2A–C). In addition,
rior infectionpotentiated theprotective efﬁcacyof a vaccine strain
f a far distant antigenic cluster (Fig. 3). The increased breadth of
b responses were not maintained beyond a year in human sero-
ogy studies [13]. However, our experiments extending the time
etween infection and immunization up to 1 year showed that
he protective immunity was easily recalled long after the initial
nfection (Supplemental Fig. 2A). Similar observations were made
y a recent trial showing that the primary Ab response was unde-
ectable in pandemic LAIV (pLAIV)-recipients, yet upon vaccination4 (2016) 495–502 501
with inactivated subvirion inﬂuenzaA (H5N1) vaccine 4 years later,
HI titers as well as Ab afﬁnity were signiﬁcantly better in pLAIV-
primed recipients than unprimed recipients who received 2 doses
of H5N1 vaccine [35].
While infection leaves a profound imprint in naïve hosts, natu-
ral infections in the general public are likely secondary responses in
nature due to pre-existing immunity to inﬂuenza. Therefore, infec-
tion events also need to be considered in the face of pre-existing,
cross-reactive immunity. Under vaccine mismatch scenarios, FM1
infectionwas attenuated by cross-reactive Abs in an infection-dose
dependent manner. While this presents the beneﬁt of mismatched
vaccination, reduced infections, in turn, dampened the subse-
quent FM1-Ab responses and protective immunity, especially in
mice infected with 0.01× LD50 FM1. While FM1-Ab responses
were reduced according to available viral Ag, %virus-speciﬁc CD8
T cells were much higher as infection was attenuated in an
infection-dose dependent manner (Fig. 4D, panel 4). Although
killed vaccine (PR8imm) poorly induced CD8 T cells, subsequent
FM1-infection accelerated the recruitment of cross-reactive CD8
T cells (PR8imm/FM1inf), demonstrating a previously unappreci-
ated role ofmismatched vaccination. Considering that lung CD103+
DC subsets are non-permissive to inﬂuenza infection, but prone
to cross-presentation to CD8 T cells [36] and our current ﬁnd-
ings on upregulation of FcRs in CD11b+ (Fig. 4D, panels 1–2) as
well as CD103+ DC subsets (data not shown) of PR8imm/FM1inf
mice, the IC-mediated cross presentation by these DC subsets is
a likely mechanism for the recruitment/expansion of pre-existing
CD8 T cells that are otherwise present at low levels. Of note, sera
from PR8-immunized mice exhibited comparable binding activ-
ity to PR8 and FM1 viruses measured by ELISA (data not shown).
Therefore, the beneﬁt of mismatched vaccination can be at two
levels; cross-neutralizing Abs immediately reduce the viral load,
while non-neutralizing, cross-reactiveAbs recruit CD8T cells. Since
vaccine mismatches are not uncommon as exempliﬁed during the
2014–2015 inﬂuenza season [37], it would be of great interest to
examine CD8 T cell responses of infection cases (vaccine failures)
and their long-termmemory responses compared to unvaccinated,
infection cases.
Overall, our ﬁndings advocate the ACIP recommendation of
inﬂuenza vaccinationdespite intermittent vaccinemismatches and
seasonal infections. For hosts with established pre-existing immu-
nity, even mismatched vaccinations provide partial protection
against infection by pre-existing Abs and elicitation of cross-
reactive T cells, yet improving vaccine formulation is worthwhile
to consider to maximize the beneﬁt of seasonal vaccinations.
Disclaimer: The ﬁndings and conclusions in this report are those
of the authors and do not necessarily represent the views of the
Centers for Disease Control and Prevention or the Agency for Toxic
Substances and Disease Registry.
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